Pharmacokinetics: Why Timing and Delivery Matter

What Is Pharmacokinetics?

Pharmacokinetics — often abbreviated PK — is the study of what your body does to a drug after you take it. It answers four fundamental questions: How does the drug get into your system (absorption)? Where does it go once it is there (distribution)? How does your body break it down (metabolism)? And how does it leave (excretion)? These four processes are sometimes abbreviated ADME, and they govern everything about how a drug works in practice — including how much you need to take, how often, and through what route.

If pharmacology tells you what a drug does to your body, pharmacokinetics tells you what your body does to the drug. Both sides of that equation matter, and understanding PK is essential for making sense of dosing, timing, and delivery method — three things that come up constantly in peptide therapy.

Absorption and Bioavailability

The first PK question is: how much of the drug you take actually makes it into your bloodstream in active form? This is called bioavailability, and it is expressed as a percentage. A drug administered by intravenous (IV) injection has 100% bioavailability by definition — it goes directly into the blood. Everything else is measured against that benchmark.

Subcutaneous injection — the most common route for peptides — typically achieves high bioavailability, often in the range of 60% to 100% depending on the specific peptide. The drug is deposited in the tissue just beneath the skin and absorbed into the bloodstream over minutes to hours.

Oral delivery presents a much bigger challenge for peptides. When you swallow a drug, it must survive stomach acid, resist digestive enzymes, cross the intestinal wall, and pass through the liver before reaching systemic circulation. This gauntlet is called first-pass metabolism, and it destroys most peptides. This is why oral bioavailability for peptides is typically very low. Oral semaglutide (Rybelsus) uses a specialized absorption enhancer called SNAC to protect the peptide and shuttle it across the stomach lining, but even with this technology, the oral bioavailability of semaglutide is only about 1% — meaning 99% of the swallowed dose never reaches the bloodstream. The dose is simply made high enough to compensate.

Other delivery routes — intramuscular injection, transdermal (through the skin via patches or creams), and intranasal — each have different bioavailability profiles. The route of administration is not just a convenience choice; it fundamentally changes how much drug reaches its target and how quickly.

Half-Life: The Clock Is Always Ticking

Once a peptide enters your bloodstream, your body immediately begins clearing it. The half-life is the time it takes for the concentration of the drug in your blood to drop by half. After one half-life, 50% remains. After two half-lives, 25% remains. After five half-lives, less than 3% remains — which is why pharmacologists generally consider a drug to be effectively cleared after five half-lives.

Half-life is the single most important factor in determining dosing frequency. A peptide with a 15-minute half-life (like natural GHRH) would need to be administered many times per day to maintain therapeutic levels. A peptide with a 7-day half-life (like semaglutide) can be administered once weekly. A peptide with a 30-hour half-life (like CJC-1295 DAC) falls somewhere in between.

The relationship between half-life and dosing is not just about convenience. It also affects whether drug levels remain stable or swing between peaks and troughs, which in turn affects both efficacy and side effects.

Cmax, Tmax, and AUC — The Key Measurements

Three measurements are central to understanding any drug's PK profile:

• Cmax (maximum concentration) — the highest concentration the drug reaches in the blood after a dose. This peak level determines whether the drug reaches a high enough concentration to be effective, and whether it reaches a high enough concentration to cause side effects.
• Tmax (time to maximum concentration) — how long after administration the drug reaches its peak. For subcutaneous peptide injections, Tmax is typically 1 to 4 hours. For oral drugs, it may be longer.
• AUC (area under the curve) — the total drug exposure over time, calculated by plotting blood concentration against time and measuring the area under that curve. AUC captures both how high the drug concentration gets and how long it stays elevated. Two drugs might have the same Cmax but very different AUCs if one is cleared faster than the other.

These measurements are not abstract. They are what clinical pharmacologists use to determine appropriate doses, dosing intervals, and whether two formulations of the same drug are truly equivalent (bioequivalence).

Steady State: When Doses Overlap

When you take a drug repeatedly on a schedule — say, a weekly injection — each new dose enters your system before the previous dose has been fully cleared. Over time, the amount of drug in your system accumulates until it reaches an equilibrium called steady state. At steady state, the amount of drug entering your system with each dose equals the amount being cleared between doses.

Reaching steady state typically takes about five half-lives. For semaglutide (half-life of ~7 days), steady state is reached after about 5 weeks of weekly dosing. This is one reason many peptide protocols involve gradual dose escalation — starting at a lower dose and increasing over weeks allows you to approach steady state gradually, reducing the likelihood of side effects that can occur when drug levels rise too quickly.

Why This Matters for Peptide Therapy

Understanding PK fundamentals empowers you to make sense of dosing protocols, delivery methods, and timing recommendations — and to recognize when advice does not align with the science. If someone recommends taking an oral peptide that has negligible oral bioavailability, you now know to question that recommendation. If a dosing protocol calls for a frequency that does not match the drug's half-life, you can spot the disconnect.

This article is for educational purposes only and does not constitute medical advice. Dosing decisions should always be made with a licensed healthcare provider who understands your individual health profile.

In the next article, we take a closer look at research quality — because not all evidence is created equal, and knowing the difference can protect you from misleading claims.